These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Mycophenolate sodium for immunosuppressive treatment in uveitis.
    Author: Deuter CM, Doycheva D, Stuebiger N, Zierhut M.
    Journal: Ocul Immunol Inflamm; 2009; 17(6):415-9. PubMed ID: 20001262.
    Abstract:
    PURPOSE: To assess the efficacy and tolerability of mycophenolate sodium (MPS) in patients with uveitis. METHODS: Retrospective analysis including uveitis patients treated with MPS (Myfortic) for at least 3 months duration. MPS was administered in a dose of 720 mg twice daily. RESULTS: We analyzed 35 patients (65 affected eyes) with anterior (n = 5), intermediate (n = 23), posterior (n = 6), and panuveitis (n = 1). Previous treatment consisted of systemic corticosteroids in all patients and at least one immunomodulating agent in 15 patients. Mean duration of MPS therapy was calculated as 9.6 months (3-31 months). MPS was able to control intraocular inflammation without relapse in 30 patients (85.7%). Stabilization or improvement of visual acuity was achieved in 60 eyes (92.3%). Tolerability of MPS was good or moderate in 34 patients (97.1%). CONCLUSIONS: MPS was demonstrated as an effective and well-tolerated immunosuppressive drug for different forms of uveitis.
    [Abstract] [Full Text] [Related] [New Search]